Scopus BioPharma SG&A Expenses 2020-2023 | SCPS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Scopus BioPharma sg&a expenses from 2020 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Scopus BioPharma sg&a expenses from 2020 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$169.8B
Vertex Pharmaceuticals (VRTX)	$121.4B
Gilead Sciences (GILD)	$109.7B
Bristol Myers Squibb (BMY)	$106.4B
Regeneron Pharmaceuticals (REGN)	$102.2B
CSL (CSLLY)	$92.8B
GSK (GSK)	$79.1B
Alnylam Pharmaceuticals (ALNY)	$36.5B
Argenex SE (ARGX)	$33.1B
BioNTech SE (BNTX)	$27.1B
Biogen (BIIB)	$26.7B
Illumina (ILMN)	$23.3B
Moderna (MRNA)	$21.2B
BeiGene (BGNE)	$21.1B
Genmab (GMAB)	$15.3B
Incyte (INCY)	$14.2B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.9B
Sarepta Therapeutics (SRPT)	$12.4B
Insmed (INSM)	$12.2B
Vaxcyte (PCVX)	$11.8B
Bio-Techne Corp (TECH)	$11.2B
QIAGEN (QGEN)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.6B
Revolution Medicines (RVMD)	$8.4B
Legend Biotech (LEGN)	$8.3B
Exelixis (EXEL)	$8.2B
Viking Therapeutics (VKTX)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B